Stocks and Investing Stocks and Investing
Fri, April 26, 2024

Matthew Harrison Maintained (BMRN) at Buy with Decreased Target to $112 on, Apr 26th, 2024


Published on 2024-10-28 10:40:32 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $115 to $112 on, Apr 26th, 2024.

Matthew has made no other calls on BMRN in the last 4 months.



There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebovitz of "Citigroup" Maintained at Hold with Decreased Target to $91 on, Thursday, April 25th, 2024
  • George Farmer of "Scotiabank" Maintained at Hold with Increased Target to $85 on, Thursday, April 25th, 2024
  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Friday, February 23rd, 2024


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $110 on, Thursday, April 25th, 2024
  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Thursday, April 25th, 2024
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $107 on, Friday, February 23rd, 2024
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $104 on, Tuesday, January 30th, 2024
Contributing Sources